Table 2.
Antibody/factor | Crude geometric mean ratio (95% CI) | p value | Adjusted geometric mean ratio (95% CI)1 | p value |
---|---|---|---|---|
Anti-Rv1733c antibodies | ||||
Uninfected | 1 | 1 | ||
LTBI | 1.374 (0.915–2.063) | 0.125 | 1.240 (0.792–1.942) | 0.346 |
APTB | 1.346 (0.916–1.974) | 0.131 | 1.370 (0.904–2.078) | 0.138 |
Anti-Rv0081 antibodies | ||||
Uninfected | 1 | 1 | ||
LTBI | 1.437 (0.761–2.714) | 0.264 | 1.382 (0.700–2.727) | 0.343 |
APTB | 1.790 (1.007–3.184) | 0.047 | 1.707 (0.956–3.046) | 0.071 |
Anti-Rv1735c antibodies | ||||
Uninfected | 1 | 1 | ||
LTBI | 1.203 (0.774–1.869) | 0.411 | 1.059 (0.651–1.722) | 0.818 |
APTB | 1.529 (1.058–2.210) | 0.024 | 1.333 (0.912–1.949) | 0.138 |
Anti-Rv1737c antibodies | ||||
Uninfected | 1 | 1 | ||
LTBI | 1.147 (0.704–1.868) | 0.581 | 1.122 (0.650–1.938) | 0.680 |
APTB | 1.479 (0.966–2.264) | 0.072 | 1.352 (0.801–2.282) | 0.259 |
Anti-CFP-10/ESAT-6 antibodies | ||||
Uninfected | 1 | 1 | ||
LTBI | 1.162 (0.682–1.981) | 0.580 | 1.019 (0.567–1.829) | 0.951 |
APTB | 2.199 (1.415–3.418) | <0.001 | 2.020 (1.279–3.190) | 0.003 |
LTBI = latent tuberculosis infection; APTB = active pulmonary tuberculosis.
1Regression analyses were performed with bootstrap confidence intervals generated from 1000 replicate samples of data. The data was from 68 individuals who were uninfected, 62 with LTBI, and 105 with APTB. Adjusting was done for age, gender, and HIV infection status. Analysis was performed on log transformed values and back-transformed to provide geometric mean ratios.